MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs).The downstream transcription factors that control responses like stress signaling, pathogen response, and hormone signaling are phosphorylated as a result of the activated MAPK.
The final protein in the cascade, a MAPK (ERK, p38, or JNK), is activated by the MAPKKK by phosphorylating a serine or threonine residue on a MAPKK. Mitogen-activated protein kinase kinase 3 (MKK3), MKK6, and occasionally MKK4 are primarily responsible for activating the p38 MAPK. Two upstream MAP2Ks, MKK4 and MKK7, control the JNK. Raf and Ras are activated by the highly homologous kinases MEK1 and MEK2, which then activate ERK mitogen-activated protein kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V84851 | TRX-COBI ((R,R)-TRX-COBI; TRX-cobimetinib) | ||
|
V2681 | U0126 | 109511-58-2 | U0126 (also known as U0126-EtOH) is a novel potent,highlyselective and non-ATP competitive inhibitor of MEK1/2 with IC50 of 0.07μM/0.06μM in cell-free assays. |
|
V0447 | U0126-EtOH | 1173097-76-1 | U0126-EtOH is a novel, selective and non-ATP competitive MEK1/2 inhibitor with potential anticviral activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
